1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285 (21): 1182–6.
2. Folkman J. Role of angiogenesis in tumour growth and metastasis. Semin Oncol 2002; 29 (Suppl. 16): 15–8.
3. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9 (6): 685–93.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9 (6): 669–76.
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86 (3): 353–64.
6. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18 (1): 4–25.
7. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997; 94 (16): 8761–6.
8. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273 (21): 13313–6.
9. Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273 (46): 30336–43.
10. Lee TH, Avraham HK, Jiang S et al. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem 2003; 278 (7): 5277–84.
11. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7 (9): 987–9.
12. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307 (5706): 58–62.
13. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002; 1 (5): 453–8.
14. Abramsson A, Berlin O, Papayan H et al. Analysis of mural cell recruitment to tumor vessels. Circulation 2002; 105 (1): 112–7.
15. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15 (11): 102–11.
16. Morikawa S, Baluk P, Kaidoh T et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002; 160 (3): 985–1000.
17. MacKenzie F, Duriez P,Wong F et al. Notch4 inhibits endothelial apoptosis via RBP-Jkappadependent and independent pathways. J Biol Chem 2004; 279 (12): 11657–63.
18. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006; 107 (6): 2223–33.
19. Carlson TR, Yan Y,Wu X et al. Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice. Proc Natl Acad Sci USA 2005; 102 (28): 9884–9.
20. Liu ZJ, Shirakawa T, Li Y et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003; 23 (1): 14–25.
21. Hainaud P, Contreres JO, Villemain A et al. The role of the Vascular Endothelial Growth Factor-Delta-like 4 ligand/Notch4-Ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 2006; 66 (17): 8501–10.
22. Baluk P, Lee CG, Link H et al. Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. Am J Pathol 2004; 165 (4): 1071–85.
23. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116 (10): 2610–21.
24. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19 (3): 843–50.
25. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57 (20): 4593–9.
26. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2 (10): 1096–103.
27. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3 (6): 401–10.
28. Inai T, Mancuso M, Hashizume H et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165 (1): 35–52.
29. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10 (2): 145–7.
30. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407 (6801): 249–57.
31. Tong RT, Boucher Y, Kozin SV et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64 (11): 3731–6.
32. Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88 (12): 1979–86.
33. Lee CG, Heijn M, di Tomaso E et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60 (19): 5565–70.
34. Osusky KL, Hallahan DE, Fu A et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7 (3): 225–33.
35. Patel N, Sun L, Moshinsky D et al. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. J Pharmacol Exp Ther 2003; 306 (3): 838–45.
36. Kamba T, Tam BY, Hashizume H et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circulatory Physiol 2006; 290 (2): H560–76.
37. Vosseler S, Mirancea N, Bohlen P et al. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005; 65 (4): 1294–305.
38. Yuan F, Chen Y, Dellian M et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93 (25): 14765–70.
39. Jain RK, Safabakhsh N, Sckell A et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998; 95 (18): 10820–25.
40. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23 (5): 1011–27.
41. Brasch R, Pham C, Shames D et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997; 7 (1): 8–74.
42. Pham CD, Roberts TP, van Bruggen N et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998; 16 (4): 225–30.
43. Borgstrom P, Gold DP, Hillan et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19 (5B): 4203–14.
44. Kim KJ, Li B,Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362 (6423): 841–4.
45. Ran S, Bivens C, Trieu V et al. Synergistic effect of albumin-bound paclitaxel (abraxane) and anti-VEGF-A antibody (avastin) on growth of orthotopic MDA-MB-231 breast tumors as well as lymphatic and pulmonary disease. Poster presented at the 2006 SABCS meeting, San Antonio, Texas, USA.
46. Pietras RJ, Chen H-W, Marquez DC. Improved anticancer therapy by targeting both breast tumor and host vascular cells with antiestrogen combined with antibodies to vascular endothelial growth factor. Poster presented at the 2006 SABCS meeting, San Antonio, Texas, USA.
47. Higgins B, Kolinsky K, Zhang Y-E et al. Antitumor activity of a combined regimen of capecitabine and bevacizumab in a xenograft model of human breast cancer. Poster presented at the 2006 SABCS meeting, San Antonio, Texas, USA.
48. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30 (Suppl. 16): 117–24.
49. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23 (4): 792–9.
50. Miller KD,Wang M, Gralow J et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94 (Suppl. 1): S6 [abstract 3].
51. Wedam SB, Low JA, Yang SX et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24 (5): 769–77.